DiamiR Announces Presentation at Extracellular Biomarkers Summit 2015

MONMOUTH JUNCTION, NJ--(Marketwired - March 11, 2015) - DiamiR Biosciences, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the company's Chief Executive Officer, Dr. Kira Sheinerman, will present and discuss the company's technology platform based on the analysis of organ-enriched microRNAs in plasma for early detection and monitoring of disease at the Extracellular Biomarkers Summit, taking place in Cambridge, MA, March 16-18.

Track: microRNA as Biomarkers and Diagnostics
Date / Time: Monday, March 16, 2015, 11:35 am ET
Location: Hyatt Regency Cambridge

About DiamiR Biosciences

DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive targeted tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's disease, Parkinson's disease, and other conditions. The proprietary technology is designed to enable effective screening and stratification of patients for clinical trials as well as disease progression and treatment monitoring. For more information, please visit the company's website at www.diamirbio.com.

Please Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results, timing, costs and regulatory review of our studies and clinical trials; the results of studies of our product candidates conducted by others; our ability to obtain future funding on acceptable terms; our ability to obtain regulatory approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights; and innovation by our competitors.